Giuseppe Opocher

List of Publications by Year
in descending order

179	10,940	41344 49	31849 101
papers	citations	h-index	g-index

185	185	185	8264
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Distinct Clinical Features of Paraganglioma Syndromes Associated With <EMPH TYPE="ITAL">SDHB</EMPH> and <EMPH TYPE="ITAL">SDHD</EMPH> Gene Mutations. JAMA - Journal of the American Medical Association, 2004, 292, 943.	7.4	821
2	A Survey on Adrenal Incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	723
3	A Survey on Adrenal Incidentaloma in Italy¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	693
4	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	21.4	478
5	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	3.6	369
6	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics, 2010, 42, 229-233.	21.4	364
7	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <EMPH TYPE="ITAL">SDHC</EMPH> Gene. JAMA - Journal of the American Medical Association, 2005, 294, 2057.	7.4	309
8	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	3.6	284
9	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
10	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1977-1995.	6.4	223
11	Surgical Versus Conservative Management for Subclinical Cushing Syndrome in Adrenal Incidentalomas: A Prospective Randomized Study. Annals of Surgery, 2009, 249, 388-391.	4.2	205
12	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	9.6	198
13	Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology, 2010, 24, 2382-2391.	3.7	179
14	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research, 2009, 69, 3650-3656.	0.9	178
15	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	7.4	174
16	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	7.0	160
17	Adrenal Incidentaloma: An Overview of Hormonal Data from the National Italian Study Group. Hormone Research, 1997, 47, 284-289.	1.8	159
18	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149

#	Article	IF	Citations
19	Insulin Resistance in Cushingâ€™s Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 529-536.	3.6	146
20	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. PLoS Genetics, 2009, 5, e1000637.	3.5	140
21	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	10.7	137
22	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	3.6	131
23	Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology, 2006, 65, 699-705.	2.4	130
24	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
25	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	3.5	125
26	Long-term prognosis of patients with pediatric pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 17-25.	3.1	121
27	Molecular characteristics in papillary thyroid cancers (PTCs) with no ¹³¹I uptake. Clinical Endocrinology, 2008, 68, 108-116.	2.4	117
28	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation, 2011, 32, 51-58.	2.5	117
29	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. Thyroid, 2012, 22, 890-896.	4.5	116
30	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 301-308.	3.7	111
31	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	3.6	111
32	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 905-913.	3.6	95
33	Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment?. Surgery, 2007, 141, 723-727.	1.9	88
34	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315.	3.7	86
35	Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. European Journal of Endocrinology, 2011, 164, 971-976.	3.7	86
36	Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine, 2014, 45, 469-478.	2.3	80

#	Article	IF	Citations
37	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
38	Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genetics in Medicine, 2018, 20, 1644-1651.	2.4	73
39	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	5.1	72
40	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). Hormone and Metabolic Research, 2012, 44, 411-414.	1.5	71
41	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89.	2.7	70
42	Somatic mosaicism in von Hippel-Lindau disease. Human Mutation, 2000, 15, 114-114.	2.5	66
43	Are we overestimating the penetrance of mutations in SDHB?. Human Mutation, 2010, 31, 761-762.	2.5	64
44	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	3.7	64
45	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
46	Genetics of pheochromocytomas and paragangliomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 943-956.	4.7	62
47	Pheochromocytoma in von Hippelâ€“Lindau disease and neurofibromatosis type 1. Familial Cancer, 2005, 4, 13-16.	1.9	57
48	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. European Journal of Endocrinology, 2010, 163, 369-376.	3.7	53
49	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
50	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine-Related Cancer, 2013, 20, 477-493.	3.1	52
51	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	3.1	52
52	Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nuclear Medicine Communications, 2013, 34, 1141-1149.	1.1	51
53	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics Journal, 2015, 15, 288-292.	2.0	48
54	Characterization of endolymphatic sac tumors and von Hippelâ€“Lindau disease in the International Endolymphatic Sac Tumor Registry. Head and Neck, 2016, 38, E673-9.	2.0	48

#	Article	IF	Citations
55	Genetic polymorphism of the renin???angiotensin???aldosterone system and arterial hypertension in the Italian population. Journal of Hypertension, 2003, 21, 1853-1860.	0.5	47
56	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
57	Long-term treatment of mineralocorticoid excess syndromes. Steroids, 1995, 60, 81-86.	1.8	45
58	Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. PLoS ONE, 2016, 11, e0156044.	2.5	45
59	Thyroid cancer <scp>GWAS</scp> identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. International Journal of Cancer, 2015, 137, 1870-1878.	5.1	44
60	Apparent mineralocorticoid excess type II. Steroids, 1994, 59, 80-83.	1.8	42
61	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
62	Impaired Release of Vitamin D in Dysfunctional Adipose Tissue: New Cues on Vitamin D Supplementation in Obesity. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2564-2574.	3.6	40
63	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. Journal of Human Hypertension, 2016, 30, 374-378.	2.2	38
64	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	11.4	37
65	Mineralocorticoid hypertension due to a nasal spray containing 9Î±-fluoroprednisolone. American Journal of Medicine, 1981, 71, 352-357.	1.5	36
66	Sodium Regulating Hormones at High Altitude: Basal and Post-Exercise Levels¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 570-574.	3.6	36
67	RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clinical Endocrinology, 2008, 69, 418-425.	2.4	36
68	Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro-Oncology, 2016, 18, 1011-1020.	1.2	36
69	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. American Journal of Pathology, 2013, 182, 350-362.	3.8	35
70	Sodium Regulating Hormones at High Altitude: Basal and Post-Exercise Levels. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 570-574.	3.6	35
71	Paraganglioma Syndrome: SDHB, SDHC, and SDHD Mutations in Head and Neck Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 190-197.	3.8	31
72	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. Endocrine-Related Cancer, 2015, 22, 191-204.	3.1	29

#	Article	IF	Citations
73	Laparoscopic adrenalectomy for pheochromocytoma: is it really more difficult?. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1323-1326.	2.4	27
74	Clinical and surgical features of lower brain stem hemangioblastomas in von Hippel-Lindau disease. Acta Neurochirurgica, 2010, 152, 287-292.	1.7	27
75	Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas?. Surgery, 2011, 150, 1194-1201.	1.9	26
76	A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocrine-Related Cancer, 2006, 13, 525-533.	3.1	25
77	The Endemic Paraganglioma Syndrome Type 1: Origin, Spread, and Clinical Expression. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E637-E641.	3.6	25
78	Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. Human Molecular Genetics, 2013, 22, 804-815.	2.9	25
79	Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes, 1990, 39, 289-298.	0.6	25
80	Genetics and Biology of Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 160-165.	1.2	23
81	Effect of Ketanserin in Primary Aldosteronism. Journal of Cardiovascular Pharmacology, 1985, 7, 172-175.	1.9	22
82	17-Î±-hydroxylase deficiency in three siblings: short- and long-term studies. Journal of Endocrinological Investigation, 1991, 14, 99-108.	3.3	22
83	Differential diagnosis in primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 1993, 45, 49-55.	2.5	21
84	68Ga-DOTA-NOC PET/CT Detects Somatostatin Receptors Expression in von Hippel-Lindau Cerebellar Disease. Clinical Nuclear Medicine, 2011, 36, 64-65.	1.3	21
85	Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results. Human Pathology, 2012, 43, 1103-1112.	2.0	21
86	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippelâ€“Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial Cancer, 2015, 14, 309-316.	1.9	21
87	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
88	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. Hormone and Metabolic Research, 1981, 13, 464-467.	1.5	20
89	Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. Journal of Endocrinological Investigation, 1987, 10, 377-382.	3.3	20
90	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney International, 1992, 41, 813-821.	5.2	20

#	Article	IF	Citations
91	Expression of type 1 angiotensin II receptors in human aldosteronomas. Endocrine Research, 1995, 21, 189-195.	1.2	20
92	Role of ultrasound and color Doppler imaging in the detection of carotid paragangliomas. Journal of Ultrasound, 2012, 15, 158-163.	1.3	20
93	18F-DOPA PET/CT in the Evaluation of Hereditary SDH-Deficiency Paraganglioma-Pheochromocytoma Syndromes. Clinical Nuclear Medicine, 2014, 39, e53-e58.	1.3	20
94	Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta Otorhinolaryngologica Italica, 2017, 37, 423-429.	1.5	20
95	Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. Acta Neuropathologica, 2018, 135, 779-798.	7.7	20
96	Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma. Clinical Endocrinology, 2003, 59, 707-715.	2.4	19
97	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. Journal of Clinical Oncology, 2011, 29, e171-e174.	1.6	19
98	Copy number variations of E2F1: a new genetic risk factor for testicular cancer. Endocrine-Related Cancer, 2017, 24, 119-125.	3.1	18
99	Opioid Modulation of Normal and Pathological Human Chromaffin Tissue*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 577-582.	3.6	17
100	Acute and Chronic Effect of Nifedipine in Primary Aldosteronism. Clinical and Experimental Hypertension, 1989, 11, 1263-1272.	0.3	17
101	Steroids and hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 35-44.	2.5	17
102	Impaired response to angiotensin II in Type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity. Diabetologia, 1991, 34, 595-603.	6.3	17
103	Molecular analysis of two uncharacterized sequence variants of the VHL gene. Journal of Human Genetics, 2006, 51, 964-968.	2.3	17
104	Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs, 2018, 29, 102-105.	1.4	17
105	Effect of Verapamil on aldosterone secretion in primary aldosteronism. Journal of Endocrinological Investigation, 1987, 10, 491-494.	3.3	16
106	Clinical and Genetic Aspects of Phaeochromocytoma. Hormone Research in Paediatrics, 2003, 59, 56-61.	1.8	16
107	Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Journal of Endocrinological Investigation, 1997, 20, 86-89.	3.3	15
108	Genetic and Clinical Investigation of Pheochromocytoma: A 22-Year Experience, from Freiburg, Germany to International Effort. Annals of the New York Academy of Sciences, 2006, 1073, 122-137.	3.8	15

#	Article	IF	Citations
109	Familial Nonsyndromic Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 149-155.	3.8	15
110	Functional Consequences of Succinate Dehydrogenase Mutations. Endocrine Practice, 2011, 17, 64-71.	2.1	15
111	Zona glomerulosa of the adrenal gland in a transgenic strain of rat: a morphologic and functional study. Cell and Tissue Research, 1994, 278, 21-28.	2.9	14
112	Role of the Genetic Study in the Management of Carotid Body Tumor in Paraganglioma Syndrome. European Journal of Vascular and Endovascular Surgery, 2008, 36, 517-519.	1.5	14
113	Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Familial Cancer, 2009, 8, 379-382.	1.9	14
114	E2F1 germline copy number variations and melanoma susceptibility. Journal of Translational Medicine, 2019, 17, 181.	4.4	14
115	Morphology and function of the adrenal zona glomerulosa of transgenic rats TGR [mREN2] 27: Effects of prolonged sodium restriction. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 155-162.	2.5	13
116	Hemangioblastoma of the obex mimicking anorexia nervosa. Neurology, 2006, 67, 178-179.	1.1	13
117	New Aspects of Mineralocorticoid Hypertension. Hormone Research, 1990, 34, 175-180.	1.8	12
118	Unilateral Adrenal Tumor, Erectile Dysfunction and Infertility in a Patient with 21-Hydroxylase Deficiency: Effects of Glucocorticoid Treatment and Surgery. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 41-43.	1.2	12
119	Factors influencing the rising rates of adrenal surgery: analysis of a 25-year experience. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 503-507.	2.4	12
120	Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension. Endocrine, 2014, 46, 340-346.	2.3	12
121	Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP). Pediatric Blood and Cancer, 2020, 67, e28332.	1.5	12
122	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	3.3	11
123	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 865-869.	3.6	10
124	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. Journal of Translational Medicine, 2015, 13, 360.	4.4	10
125	Renin-Angiotensin-Aldosterone System: A Long-Term Follow-Up Study in 17Î±-Hydroxylase Deficiency Syndrome (17OHDS). Clinical and Experimental Hypertension, 1986, 8, 773-780.	0.3	9
126	3 Adrenal complications of HIV infection. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 769-776.	1.0	9

#	Article	IF	Citations
127	Natriuretic peptides receptors in human aldosterone-secreting adenomas. Journal of Endocrinological Investigation, 1999, 22, 514-518.	3.3	9
128	An Epistatic Interaction between the PAX8 and STK17B Genes in Papillary Thyroid Cancer Susceptibility. PLoS ONE, 2013, 8, e74765.	2.5	9
129	Spectrum of magnetic resonance imaging findings in pancreatic and other abdominal manifestations of Von Hippel-Lindau disease in a series of 23 patients: a pictorial review. JOP: Journal of the Pancreas, 2014, 15, 1-18.	1.5	9
130	Peripheral and Renal Vein Plasma Renin Activity in Hypertensive Urological Patients. British Journal of Urology, 1982, 54, 348-353.	0.1	8
131	Lack of aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies. Journal of Endocrinological Investigation, 1989, 12, 13-17.	3.3	8
132	Atrial Natriuretic Peptide Infusion in Primary Aldosteronism: Renal, Hemodynamic and Hormonal Effects. American Journal of Hypertension, 1990, 3, 668-673.	2.0	8
133	Aldosterone, Calcium, and Hypertension. American Journal of Nephrology, 1986, 6, 33-39.	3.1	7
134	Atrial natriuretic peptide in Cushingâ€™s disease. Journal of Endocrinological Investigation, 1990, 13, 133-137.	3.3	7
135	Hypertensive congenital adrenal enzymatic defects detected by high-performance liquid chromatography of corticosteroids. Journal of Chromatography A, 1991, 553, 201-204.	3.7	7
136	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
137	Role of atrial natriuretic peptide in the pathogenesis of sodium retention in IDDM with and without glomerular hyperfiltration. Diabetes, 1992, 41, 936-945.	0.6	7
138	RET codon 609 mutations: a contribution for better clinical managing. Clinics, 2012, 67, 33-36.	1.5	7
139	Atrial Natriuretic Peptide (ANP) increases in the mangrove crab Ucides cordatus when exposed to increased environmental salinity. Comparative Biochemistry and Physiology A, Comparative Physiology, 1992, 101, 803-806.	0.6	6
140	Effects of highâ€altitude chronic hypoxia on platelet Î± 2 â€receptors in man. European Journal of Clinical Investigation, 1997, 27, 316-321.	3.4	6
141	Role of SDHAF2 and SDHD in von Hippelâ€“Lindau Associated Pheochromocytomas. World Journal of Surgery, 2014, 38, 724-732.	1.6	6
142	Improving Outcomes in Carotid Body Tumors Treatment: The Impact of a Multidisciplinary Team Approach. Annals of Vascular Surgery, 2021, 75, 315-323.	0.9	6
143	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 865-869.	3.6	6
144	Atrial natriuretic factor in hypertensive and normotensive insulin-dependent diabetics. Journal of Hypertension, 1989, 7, S236-237.	0.5	5

#	Article	IF	Citations
145	Usefulness of Atrial Natriuretic Peptide Assay in Primary Aldosteronism. American Journal of Hypertension, 1992, 5, 811-816.	2.0	5
146	Difficulties in the Mutation Analysis of Plasminogen Gene: A Study in Two Patients with Ligneous Conjunctivitis. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 77-84.	1.7	5
147	Coexistence of VHL Disease and CPT2 Deficiency: A Case Report. Cancer Research and Treatment, 2016, 48, 1438-1442.	3.0	5
148	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
149	Effect of indomethacin on urinary kallikrein excretion in Bartterâ€™s syndrome of the adult. Journal of Endocrinological Investigation, 1981, 4, 17-20.	3.3	4
150	Effect of Verapamil on the Aldosterone-Stimulating Properties of Metoclopramide: In Vitro and In Vivo Studies. Hormone and Metabolic Research, 1986, 18, 775-778.	1.5	4
151	11Î²-hydroxylase deficiency. Journal of Endocrinological Investigation, 1995, 18, 545-549.	3.3	4
152	Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. The Journal of Steroid Biochemistry, 1983, 19, 531-536.	1.1	3
153	Impact of High Performance Liquid Chromatography on Assay of Steroid Hormones. Annals of the New York Academy of Sciences, 1990, 595, 480-483.	3.8	3
154	The pheochromocytoma and paraganglioma syndrome: Founder effects and the PGL 1 syndrome. Annales D'Endocrinologie, 2009, 70, 157-160.	1.4	3
155	Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease. European Radiology, 2015, 25, 2025-2032.	4.5	3
156	Effect of Lacidipine on Pituitary Function in Essential Hypertension. Journal of Cardiovascular Pharmacology, 1991, 18, S26-S28.	1.9	2
157	Body fluids, atrial volumes and atrial natriuretic peptide during and after high-altitude exposure. Wilderness and Environmental Medicine, 1995, 6, 11-19.	0.9	2
158	Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Anti-Cancer Drugs, 2015, 26, 232-235.	1.4	2
159	Retinal abnormalities associated with a mutation of the nucleotide 683 in von Hippel-Lindau disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 615-620.	1.9	1
160	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 963.	3.7	1
161	OECI Accreditation at Veneto Institute of Oncology IOV - IRCCS, General Framework and Multidisciplinary Approach. Tumori, 2015, 101, S38-S41.	1.1	1
162	Resistance to the actions of atrial natriuretic factor in insulin-dependent diabetic hypertensives and improvement with angiotensin converting enzyme inhibitor treatment. Journal of Hypertension, 1991, 9, S264.	0.5	1

#	Article	IF	Citations
163	Urinary Steroid Profiling as a High-Throughput Screening Tool for the Detection of Malignancy in Patients with Adrenal Tumors.. , 2010, , P3-72-P3-72.		1
164	First-line sunitinib in patients with renal cell carcinoma (RCC) and von Hippel-Lindau syndrome (VHL).. Journal of Clinical Oncology, 2011, 29, 373-373.	1.6	1
165	217. Effect of metoclopramide on plasma aldosterone: in vivo and in vitro studies. The Journal of Steroid Biochemistry, 1978, 9, 858.	1.1	0
166	A sensitive immunoassay for nerve growth factor determination. Pharmacological Research, 1990, 22, 463.	7.1	0
167	Molecular diagnosis of inherited diseases. Clinica Chimica Acta, 1999, 280, 73-80.	1.1	0
168	Molecular Diagnosis of von Hippel-Lindau Disease. , 2001, 136, 263-270.		0
169	11 $beta;-hydroxysteroid-dehydrogenase type 2 gene analysis in hypertensive and normotensive subjects. American Journal of Hypertension, 2003, 16, A81.	2.0	0
170	Pheochromocytoma â€“ where are we? Where should we go? A medical and scientific odyssey. Familial Cancer, 2005, 4, 1-1.	1.9	0
171	La malattia di von Hippel-Lindau. L Endocrinologo, 2007, 8, 102-108.	0.0	0
172	Gene expression analysis in pheochromocytoma â€“ searching for new pathways involved in the hereditary susceptibility and the malignant outcome. European Journal of Cancer, Supplement, 2008, 6, 160-161.	2.2	0
173	Adrenal and Renal Physiology, and Medical Renal Disease. Journal of Urology, 2010, 184, 1301-1302.	0.4	0
174	Diagnosi e terapia della sindrome paraganglioma. L Endocrinologo, 2011, 12, 170-178.	0.0	0
175	[PP.07.12] ARMC5 MUTATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM AND BILATERAL ADRENAL LESIONS. Journal of Hypertension, 2016, 34, e156-e157.	0.5	0
176	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2021, , 325-344.	0.1	0
177	Von Hippel-Lindau disease and multispecialist team. Journal of Neurosurgical Sciences, 2021, 65, 213-215.	0.6	0
178	Identification and stratification of pheochromocytomas/paragangliomas with SDHx mutations using the succinate to fumarate ratio. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
179	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2019, , 1-20.	0.1	0